A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus

Current Medical Research and Opinion

Volumn 21, Issue 12, 2005, Pages 2051-2061

  Swift, James A ^a   Conway, Peter ^b   Purdie, David W ^c  

^a Ashfield Healthcare   (United Kingdom)

^b PFIZER INC   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cost utility analysis; Hormone replacement therapy; Menopause; Quality adjusted life years

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE;

AMENORRHEA; ARTICLE; BREAST TENDERNESS; CANDIDIASIS; COHORT ANALYSIS; COMPARATIVE STUDY; CONSULTATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DOSE CALCULATION; DRUG COST; DRUG DOSE REGIMEN; DRUG MEGADOSE; ESTROGEN THERAPY; HUMAN; LOW DRUG DOSE; MASTALGIA; MENOPAUSAL SYNDROME; PATIENT COMPLIANCE; POSTMENOPAUSE; PROBABILITY; SAMPLE SIZE; SENSITIVITY ANALYSIS; TREATMENT WITHDRAWAL; UTERINE CERVIX; VAGINA BLEEDING;

COST-BENEFIT ANALYSIS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE;

EID: 29144536257     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X75113     Document Type: Article

References (43)

1. McNagny SE. Prescribing hormone replacement therapy for menopausal symptoms. Ann Intern Med 1999;131:605-16
2. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-71
3. Glass S, Rosenblum G. The rational use of oral estrogens in the menopause. West J Surg Obstet Gynecol 1943;51:4-7
4. Sturdee DW, Wade-Evans T, Paterson ME, et al. Relations between bleeding pattern, endometrial histology, and oestrogen treatment in menopausal women. Br Med J 1978;1:1575-7
5. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92:982-8
6. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994;83:686-92
7. Lobo RA, Pickar JH, Wild RA, et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol 1994;84:987-95
8. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57
9. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66
10. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
11. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84
12. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53
13. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
14. Design of the Women's Health Initiative Clinical Trial and Observational Study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109
15. Lobo RA, Bush T, Carr BR, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001;76:13-24
16. Pickar JH, Yeh IT, Wheeler JE, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003;80:1234-40
17. Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-7
18. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-79
19. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-76
20. British Medical Association. British National Formulary (BNF). London, 2004
21. Scottish Medicines Consortium. Summary of Advice. Conjugated oestrogen, medroxyprogesterone (Premique Low Dose) 8 Nov 2004. Available from www.scottishrnedicines.org.uk/updocs/Premique%201ow%20dose.pdf [Last accessed 09 June 2005]
22. Lawrence M, Jones L, Lancaster T, et al. Hormone replacement therapy: patterns of use studied through British general practice computerized records. Fam Pract 1999;16:335-42
23. Loh FH, Chen LH, Yu SL, et al. The efficacy of two dosages of a continuous combined hormone replacement regimen. Minnesota: Health Technology Advisory Committee, 2002
24. Wren B, Brown L. Compliance with hormonal replacement therapy. Minnesota: Health Technology Advisory Committee, 1991
25. Vihtamaki T. Why do postmenopausal women discontinue HRT? Minnesota: Health Technology Advisory Committee, 1999
26. Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 1999;6:282-9
27. Ryan PJ, Harrison R, Blake GM, et al. Compliance with hormone replacement therapy (HRT) after screening for post-menopausal osteoporosis. Br J Obstet Gynaecol 1992;99:325-8
28. Karakoc B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause 1998;5:102-6
29. Sturdee DW. The importance of patient education in improving compliance. Climacteric 2000;3(Suppl 2):9-13
30. Health Technology Advisory Committee. Postmenopausal hormone replacement. Minnesota: Health Technology Advisory Committee, 2002
31. den Tonkelaar I, Oddens BJ. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol 2000;95:507-12
32. Li C, Samsioe G, Lidfelt J, et al. Important factors for use of hormone replacement therapy: a population-based study of Swedish women. The Women's Health in Lund Area (WHILA) Study. Menopause 2000;7:273-81
33. Regan MM. Why do older women discontinue HRT? J Women's Health Gend Based Med 2001;10:343-50
34. Bjorn I, Backsrom T. Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Maturitas 1999;32:77-86
35. Doren M, Schneider HP. The impact of different HRT regimens on compliance. Int J Fertil Menopausal Stud 1996;41:29-39
36. Abacus International. Data on file. 2005
37. MIMS, Monthly Index of Medical Specialities. London: Haymarket Medical Publications Ltd, 2004
38. Netten A, Curtis L. Unit costs of health and social care 2003. Canterbury, UK: PSSRU Personal Social Services Research Unit, 2003
39. ISD. Costs book 2003. Available from: www.isdscotland.org/isd/files/ Costs_2003.pdf [Last accessed 09 June 2005]
40. Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993;307:836-40
41. Consensus Conference on Hormone Replacement Therapy. Final Consensus Statement. Available from www.rcpe.ac.uk. 2003 [Last accessed 22 Sept 2005]
42. UK Department of Health. Population figures at SHA and PCO level for England and Wales. Available from: www.dh.gov. uk/PublicationsAndStatistics/ Statistics/StatisticalWorkAreas/StatisticalHealthCare/ StatisticalHealthCareArticle/fs/en?CONTENT_ID=4001584&chk=LubbNc [Last accessed 09 June 2005]
43. Adelphi Research UK. Data on file. 2005